BBI-825
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor
Conditions
Solid Tumor
Trial Timeline
Mar 28, 2024 → Jun 25, 2025
NCT ID
NCT06299761About BBI-825
BBI-825 is a phase 1 stage product being developed by Boundless Bio for Solid Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT06299761. Target conditions include Solid Tumor.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06299761 | Phase 1 | Terminated |
Competing Products
20 competing products in Solid Tumor